Compare Amphastar Pharmaceuticals Inc (AMPH) vs ConocoPhillips (COP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs ConocoPhillips — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.45 (market cap $863.95M), while ConocoPhillips trades at $125.76 (market cap $147.80B). The key difference: ConocoPhillips is far larger — about 171.1× Amphastar Pharmaceuticals Inc's market cap, and ConocoPhillips pays a 2.73% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | COP | |
|---|---|---|
Market Cap | $863.95M | $147.80B |
Sector | Health | Energy |
52-Week High | $30.81 | $133.80 |
52-Week Low | $16.87 | $85.66 |
Enterprise Value | $1.26B | $163.40B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
ConocoPhillips (COP) trades at $117.61, up 0.73% today, with a bullish technical signal from moving averages and a consensus analyst price target of $149.25. Recent Q2 2026 earnings beat expectations with EPS of $3.24 versus $2.90 estimated, driven by strong Permian Basin output and higher oil prices. The company reaffirmed its $7 billion free cash flow target by 2029 and completed a $1.7 billion asset sale ahead of schedule.
Outlook is positive due to robust operational performance and favorable oil market trends, but risks include commodity price volatility and CEO transition. The stock offers value with a P/E of 15.56 and a net income margin of 14.65%, supported by 74.51% analyst buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →
